Popular search terms:
Search Results
11 results found-
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
https://www.csl.com/news/2020/20201009-first-patient-enrolled-in-nih-covid19-phase-3-trial -
• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.
https://www.csl.com/news/2020/20200730-perreault-urges-plasma-donations-at-white-house-roundtable -
Partnered Projects #LCM includes direct post marketing commitments as well as pathogen safety, capacity expansions, yield improvements, new packages and sizes for all registered products Progress through Stage Gates in 2013
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2013.pdf -
Driven by Our Promise TM Progress Through Stage Gates in 2018
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2018.pdf -
10 Global Progress Through Stage Gates in 2017
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2017.pdf -
Partnered Projects #LCM includes direct post marketing commitments as well as pathogen safety, capacity 8 expansions, yield improvements, new packages and sizes for all registered products Global Progress Through Stage Gates in 2016
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2016.pdf -
Partnered Projects #LCM includes direct post marketing commitments as well as pathogen safety, capacity expansions, yield improvements, new packages and sizes for all registered products Progress through Stage Gates in 2014
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2014.pdf -
Partnered Projects 9 #LCM includes direct post marketing commitments as well as pathogen safety, capacity expansions, yield improvements, new packages and sizes for all registered products Global Progress through Stage Gates in 2015
https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2015.pdf -
Prior to Takeda, Dr Yamada was President of the Bill & Melinda Gates Foundation Global Health Program and prior to that was Chairman of Research and Development at GlaxoSmithKline.
https://www.csl.com/-/media/csl/documents/february-2019-csl-prospectus_final.pdf -
and Warner Lambert Co./Vice President Megan Clark, Current From 2016 Non-Executive Director Non-Executive Current From 2014 Director Rio Tinto Director Current From 2010 Bank of America Merrill Lynch/Member of Australian advisory board Past From 2009 to Commmonwalth Scientific and Industrial Research Organisation/ 2014 CEO Past From 2003 to BHP Billiton/ Vice President 2008 Tadataka Current From 2016 Non-Executive Director Yamada, Current From 2011 Agilent Technologies, Inc./ Director Non-Executive Current From 2015 Frazier Healthcare Partners/ Venture Partner Past From 2007 to Covidien/ Director Director 2011 Past From 2011 to Takeda Pharmaceuticals/ Chief Medical and Scientific Officer and 2015 Director Past From 2006 to Bill & Melinda Gates Global Health Program/ President 2011 Past From 2000 to GlaxoSmithKline/Chairman of R&D (2000-2006) and Director (2004- 2006 2006) Past From 1996 to SmithKline Beecham/Chairman of R&D and Director 2000 David Lamont, Current From 2016 Chief Financial Officer Chief Financial Past From 2010 - MMG/CFO Officer 2016 Past From 1999 to Served as CFO of several leading multinational companies including Past 2010 MMG Limited, Oz Minerals Limited, PaperlinX Limited, BHP Bil- lington's energy and coal and carbon steel materials division and Incitec Pivot Limited Andrew Cuth- Current From 2000 Chief Scientific Officer and R&D Director.
https://www.csl.com/-/media/shared/documents/approved-csl-prospectus-for-communication.pdf